DNA Vaccines: Technologies and Global Markets - new market research report published

companiesandmarkets.com

2012-11-30 09:29:33 - DNA Vaccines: Technologies and Global Markets - a new market research report on companiesandmarkets.com

- Overall sales in the DNA vaccines market were worth $141 million in 2008, and increased to an estimated $193 million in 2009. By 2014, it is projected to increase substantially to $2.7 billion, for a 5-year compound annual growth rate (CAGR) of 69.5%.- The human health vaccine segment was valued at $12 million in 2008. This is expected to

 

 

increase to nearly $24 million in 2009, and is projected to reach almost $2.3 billion in 2014, for a 5-year CAGR of 149.6%.- Sales in the research tools segment amounted to $73 million in 2008, increased to nearly $92 million in 2009, and are projected to reach nearly $166 million in 2014, for a 5-year CAGR of 12.6%.
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular biology, DNA synthesis, and immunobiology enable rational design approaches. These technologies allow highly targeted vaccines aimed at specific epitopes. The result is new vaccines for a wider range of diseases than was previously feasible, including a new class of therapeutic vaccines. These new technologies allow pharmaceutical firms to discover and develop high-value vaccines for novel applications, creating a substantial new market opportunity.

DNA vaccines have many potential advantages, including specific targeting, use of multiple genes to enhance immunity, and reduced risk compared with conventional vaccines. Translating the advantages of DNA vaccines into the clinic has historically been difficult; however, new advances in the fields of vaccine design and DNA delivery are addressing the previous issues. Achievements in these fields promise to overcome the translational hurdles and create strategic opportunity. This report analyzes these trends and their effects on the future markets for DNA vaccines.

The technological and structural changes occurring in the vaccine industry are strong driving forces for revitalizing this particular market and providing new growth opportunities. It is important that biotechnology and pharmaceutical firms understand the technology and market dynamics within this industry in order to best develop strategic plans and actions.

Based on these market and technology dynamics, it is especially timely to examine the future DNA vaccines markets.

INTENDED AUDIENCE

We have compiled a study of DNA vaccine technologies that will be commercially important in the major market segments, including cancer, infectious diseases, animal health, allergies, and biodefence.

We present DNA vaccine delivery and synthesis technologies; growth driving forces; product formats; market applications; clinical trials; industry structure and alliances; and global sales forecasts for the period 2009 through 2014. We estimate the future use of DNA vaccines in the important disease markets, and by technology.

This report will serve as a useful industry guide for biotechnology, DNA plasmid, gene therapy, DNA delivery, pharmaceutical, vaccine, animal health, and biodefence companies; as well as for suppliers of genetic tools, synthetic genes, and vaccine adjuvants. It will also be of interest to professionals within the regulatory agencies to understand the scope and pace of DNA vaccine technologies as they move from clinical trials into the market.

SCOPE OF REPORT

The study scope includes DNA vaccine products that are commercial or likely to be commercialized within the next 5 years. Both human and animal health markets are studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2009 through 2014 is estimated.

The role that DNA vaccines play in the overall vaccines industry is examined, as well as how the vaccine industry structure and dynamics are changing.

We examine DNA synthesis, biotechnology, and pharmaceuticals firms; strategic industry alliances; and the role of gene delivery and synthesis technologies. The major markets for DNA vaccines, including infectious diseases, cancers, animal health, allergies, and biodefense, are analyzed and the main companies in these fields are highlighted.&

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.